Arecor presents positive data from phase I clinical trial of ultra-concentrated ultra-rapid acting insulin AT278
- AT278 delivers significantly accelerated early PK/PD profile compared with NovoRapid® in people with Type 2 Diabetes and high BMI
Closed Loop Medicine appoints Luba Greenwood as Chair of the Board of Directors
Appointment of notable investor and executive in healthcare and tech to support leadership team in preparation for commercial milestones
Cellular Origins and 3P innovation collaborate to accelerate industrialisation of CGT manufacturing
Partnership to integrate 3P innovation’s cryoFIL cryovial filling platform within Cellular Origins’ robotic system, Constellation
Enterprise Therapeutics appoints Annabella Amatulli as Head of Regulatory Affairs
Appointment brings extensive regulatory experience as lead asset ETD001 progresses through Phase 2 clinical trial for treatment of cystic fibrosis
Engagement and motivation at work: what's the difference?
At work, you’ve probably heard people throwing around the terms “motivation” and “engagement” like they’re the same thing. Spoiler alert: They’re not. While both are crucial for driving employee performance and satisfaction, they represent distinct aspects of how we experience the workplace.
Health Innovation East and 42T webinar to help power Net Zero NHS
Health Innovation East, the innovation arm of the NHS in the East of England and 42 Technology (42T), a product design and innovation consultancy, are co-hosting a free webinar aimed at helping the NHS achieve its ambitious net zero goals.
HOPE: Cleanroom Solutions facilitating greatness with elite large-scale turnkey construction builds
Guardtech Group’s complex cleanroom facility construction brand celebrating their role as facilitators of groundbreaking Life Science and R&D innovation
o2h technology announces the launch of the third edition of the Tech Kickstarter Competition
Cambridge, UK: o2h technology, a business vertical of the o2h group, is thrilled to announce the launch of the third edition of its Tech Kickstarter Competition. This initiative is designed to support innovative seed and early stage companies by helping them meet their MVP, web, and mobile app development needs.
Common diabetes drug slows growth of normal cells carrying cancer mutation
A common diabetes medication, metformin, slows the growth of precancerous cells in the oesophagus while some metabolic conditions accelerate it, suggests a new study.
PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes
Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER™ platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan Milner, Amadeus Capital andNanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman
Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind Appointment of Edwin Moses as Chairman to support the leadership team in maximising the value of thMeet Cambridge helps to bring international neurotrauma conference to the city
The official bureau for conferences and events in Cambridge and the surrounding area is seeing the culmination of five years’ preparation as partner to the organising committee for one of the world’s largest medical conferences in its field.
CMR Surgical strengthens senior team
CMR Surgical, the global surgical robotics business, announces the appointment of Markus Bauman as Chief Legal & Business Affairs Officer, joining the Company’s executive leadership team.
Natural probiotic discovered in UK newborns' microbiomes
Newborn babies have one of three pioneer bacteria in their gut shortly after birth, one of which could be used to develop new personalised infant therapeutic probiotics, researchers show.
Newcells Biotech launches Lung Ciliary Beat Frequency assay to enhance safety and efficacy profiling in preclinical drug development
Application of new CiliaBeat software to provide reliable and predictive data on the impact of drugs on cilia function Assay leverages Newcells’ complex lung small airway in vitro model to enable highly sensitive assessment of drug efficacy and chemical safety as pa
ARU vision research shortlisted for national awards
Anglia Ruskin University nominated in two categories by Times Higher Education.
Qkine expands senior leadership
Qkine expands senior leadership with the appointment of Rob Nixon, Commercial Director, and Paul Grafham, Chief Financial Officer.
Unlocking opportunities in China's thriving Life Sciences market
As the second-largest healthcare market in the world, China is on an extraordinary trajectory of growth, with its life sciences sector expected to triple in size by 2030. This is an exciting time for UK life science companies looking to expand their horizons. Excellence First Enterprise Consultancy Ltd (EFEC) specialise in providing in2China services, designed specifically for UK firms eager to…
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement
Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applicationsDublin, Ireland, and Cheshire, UK: ERS Genomics Limited, the CRISPR licensing Company, and Medicines Disco
From farms to factories: patient journey to Pulmonary Fibrosis
Rosemary’s health journey has been anything but straightforward. After enduring three years of painful breathing tests with countless visits to her GP and specialist consultants, she was finally given a diagnosis 12 months later—a name that escaped her when her granddaughter asked.
Sapio Sciences advances the world's first AI-powered lab assistant
Sapio ELaiN couples AI and natural language processing to deliver the future interface for scientists and lab operations
Nxera Pharma to receive US$35 Million from Neurocrine Biosciences upon positive phase 2 data for partnered Schizophrenia candidate NBI-1117568
Tokyo, Japan and Cambridge, UK - Nxera Pharma Co., Ltd. - formerly known as Sosei Group or Sosei Heptares – announces it will receive a US$35 million payment from Neurocrine Biosciences, triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as announced on 28 August 2024. Receipt of the US$35 million payment will be recognized as one…
Milner Therapeutics Institute 2024 symposium visual branding
I've been visual branding for the Milner Therapeutics Institute symposium since 2016 and designed the Milner Therapeutics Institute logo and built the original website (now in the hands of Nikki). I've been lucky to work each year with the team to develop their event branding.
eg technology launch EU office as they partner with Galway-based PorterShed
eg technology is pleased to announce our partnership with PorterShed in Galway, Ireland, as we open our first office directly servicing the EU market.